Sirtuins, Cell Senescence, and Vascular Aging

• Published in: Canadian journal of cardiology 2016-05, Vol.32 (5), p.634-641
• Main Authors: Kida, Yujiro, MD, PhD, Goligorsky, Michael S., MD, PhD
• Format: Article
• Language: English
• Subjects: Aging - physiology; Cardiovascular; Cardiovascular Diseases - metabolism; Cardiovascular Diseases - physiopathology; Cell Survival; Cellular Senescence - genetics; Cellular Senescence - physiology; Endothelium, Vascular - metabolism; Homeostasis; Humans; Myocytes, Smooth Muscle - metabolism; Sirtuins - metabolism; Telomere - physiology
• ISSN: 0828-282X; 1916-7075
• DOI: 10.1016/j.cjca.2015.11.022

Abstract The sirtuins (SIRTs) constitute a class of proteins with nicotinamide adenine dinucleotide-dependent deacetylase or adenosine diphosphate-ribosyltransferase activity. Seven SIRT family members have been identified in mammals, from SIRT1, the best studied for its role in vascular aging, to SIRT7. SIRT1 and SIRT2 are localized in the nucleus and cytoplasm. SIRT3, SIRT4, and SIRT5 are mitochondrial, and SIRT6 and SIRT7 are nuclear. Extensive studies have clearly revealed that SIRT proteins regulate diverse cell functions and responses to stressors. Vascular aging involves the aging process (senescence) of endothelial and vascular smooth muscle cells. Two types of cell senescence have been identified: (1) replicative senescence with telomere attrition; and (2) stress-induced premature senescence without telomere involvement. Both types of senescence induce vascular cell growth arrest and loss of vascular homeostasis, and contribute to the initiation and progression of cardiovascular diseases. Previous mechanistic studies have revealed in detail that SIRT1, SIRT3, and SIRT6 show protective functions against vascular aging, and definite vascular function of other SIRTs is under investigation. Thus, direct SIRT modulation and nicotinamide adenine dinucleotide stimulation of SIRT are promising candidates for cardiovascular disease therapy. A small number of pilot studies have been conducted to assess SIRT modulation in humans. These clinical studies have not yet provided convincing evidence that SIRT proteins alleviate morbidity and mortality in patients with cardiovascular diseases. The outcomes of multiple ongoing clinical trials are awaited to define the efficacy of SIRT modulators and SIRT activators in cardiovascular diseases, along with the potential adverse effects of chronic SIRT modulation.